Treatment-focused Ebola trials, supportive care and future of filovirus care.
During the 2014-2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.
['Keshtkar-Jahromi|Maryam|M|', 'Martins|Karen A O|KAO|', 'Cardile|Anthony P|AP|', 'Reisler|Ronald B|RB|', 'Christopher|George W|GW|', 'Bavari|Sina|S|']
D000818:Animals D000998:Antiviral Agents D004196:Disease Outbreaks D017277:Drug Approval D015195:Drug Design D004359:Drug Therapy, Combination D029043:Ebolavirus D016563:Filoviridae D018702:Filoviridae Infections D019142:Hemorrhagic Fever, Ebola D006801:Humans
Ebola supportive care Filovirus therapeutics Clinical Trials